Original Research

Published on 23 Aug 2024

Dexmedetomidine: a real-world safety analysis based on FDA adverse event reporting system database

in Drugs Outcomes Research and Policies

Yichun Shuai
Zhe Chen
Qiaoqian Wan
Jinzheng Wu
Xin Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1419196

1,447 views

Original Research

Published on 21 Aug 2024

Initial dosage optimization of olanzapine in patients with bipolar disorder based on model-informed precision dosing: a study from the real world

in Drugs Outcomes Research and Policies

Xiao Chen
Ke Hu
Hao-Zhe Shi
Liang Chen
Yi-Jia Zhang
Su-Mei He
Cun Zhang
Dong-Dong Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1444169

917 views

Original Research

Published on 20 Aug 2024

Effects of transparent online open procurement on prices, volumes, and costs of medicines: an interrupted time series study in Ningxia, China

in Drugs Outcomes Research and Policies

Jingying Gao
Chaojie Liu
Yinming Li
Xizhuo Chen
Tianqin Xue
Yuqing Tang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1362374

626 views

Review

Published on 19 Aug 2024

The burden of systemic therapy administration route in treating HER2-positive breast cancer (for patients, healthcare professionals, and healthcare system): a systematic literature review

in Drugs Outcomes Research and Policies

Luciana Castro Garcia Landeiro
Tamie de Camargo Martins
Ruth Bartelli Grigolon
Isabel Monteiro
Joana Bisol Balardin
Eduardo Padilha
Gilberto Amorim
Stephen Stefani

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1338546

1,347 views

Original Research

Published on 16 Aug 2024

Use of the BRANT-MERQS scoring table for the quality assessment of type 3 medication review in patients with rheumatoid arthritis and those with type 2 diabetes mellitus

in Drugs Outcomes Research and Policies

Anneleen Robberechts
Kaat Stas
Margot Puttemans
Laura Poppe
Stephane Steurbaut
Guido R. Y. De Meyer
Hans De Loof

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1359568

849 views

Original Research

Published on 15 Aug 2024

Potentially inappropriate prescribing among older adults with hypertension in China: prevalence and related comorbidities across different outpatient settings

in Drugs Outcomes Research and Policies

Jiaqi Chen
Shuang Wang
Lvliang Lu
Yujie Yang
Kai Wang
Jing Zheng
Zhijiang Zhou
Pi Guo
Yunpeng Cai
Qingying Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1439230

871 views

Original Research

Published on 14 Aug 2024

Cost-effectiveness of pembrolizumab plus chemotherapy vs. chemotherapy as first-line treatment for advanced biliary tract cancer in China and the US

in Drugs Outcomes Research and Policies

Xianmei Luo
Tingting Cai
Jinyan Wu
Xingyu Li
Xiaofan Wang
Haiying Ma

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1393559

1,259 views

Original Research

Published on 13 Aug 2024

Assessing the real-world safety of tralokinumab for atopic dermatitis: insights from a comprehensive analysis of FAERS data

in Drugs Outcomes Research and Policies

Kaidi Zhao
Yang Zhao
Shengxiang Xiao
Chen Tu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1458438

2,734 views

Original Research

Published on 13 Aug 2024

Self-medication of adults and children in Poland - results from outpatient health care physicians online questionnaire

in Drugs Outcomes Research and Policies

Karolina Kłoda
Mateusz Babicki
Aleksander Biesiada
Małgorzata Gałązka-Sobotka
Iwona Kowalska-Bobko
Agnieszka Mastalerz-Migas

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1413811

1,363 views

Original Research

Published on 12 Aug 2024

A disproportionality analysis of low molecular weight heparin in the overall population and in pregnancy women using the FDA adverse event reporting system (FAERS) database

in Drugs Outcomes Research and Policies

Huanying Xu
Ningning Xu
Yingju Wang
Haoxi Zou
Suzhen Wu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1442002

1,943 views

Original Research

Published on 09 Aug 2024

Adverse event reporting of the IGF-1R monoclonal antibody teprotumumab: a real-world study based on the US food and drug administration adverse event reporting system

in Drugs Outcomes Research and Policies

Jiawei Zhao
Yong Tao

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1393940

1,847 views

Original Research

Published on 09 Aug 2024

Impact of changes in antihypertensive medication on treatment intensity at hospital discharge and 30 days afterwards

in Drugs Outcomes Research and Policies

Nuša Japelj
Mojca Kerec Kos
Maja Jošt
Lea Knez

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1376002

607 views

Original Research

Published on 07 Aug 2024

Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS)

in Drugs Outcomes Research and Policies

Ming-Tao Wen
Jia-Cheng Li
Bo-Wen Lu
Hua-Rong Shao
Pei-Xue Ling
Fei Liu
Gang Li
Di Luo

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1391356

2,474 views
2 citations

Data Report

Published on 06 Aug 2024

History of trastuzumab: a case study in health technology reassessment and natural disinvestment in Veneto Region

in Drugs Outcomes Research and Policies

Antonella Giorgia Becchetti
Anna Martini
Giovanna Scroccaro
Roberta Joppi

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1406351

1,065 views

Original Research

Published on 05 Aug 2024

Real-world pharmacovigilance analysis of galsulfase: a study based on the FDA adverse event reporting system (FAERS) database

in Drugs Outcomes Research and Policies

Shangze Li
Runcheng Huang
Yuanyuan Meng
Yijia Liu
Jiao Qian
Junjie Zou
Jun Yang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1420126

1,706 views

Original Research

Published on 05 Aug 2024

Retrospective analysis of the effect of SGLT-2 inhibitors on renal function in patients with type 2 diabetes in the real world

in Drugs Outcomes Research and Policies

Rongjing Song
Qiaoyu Hou
Xiuying Zhang
Wei Zhao
Gang Liu
Meng Li
Xiaohong Zhang
Linong Ji

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1376850

1,384 views

Navigation group

Articles

Dexmedetomidine: a real-world safety analysis based on FDA adverse event reporting system database

Initial dosage optimization of olanzapine in patients with bipolar disorder based on model-informed precision dosing: a study from the real world

Effects of transparent online open procurement on prices, volumes, and costs of medicines: an interrupted time series study in Ningxia, China

The burden of systemic therapy administration route in treating HER2-positive breast cancer (for patients, healthcare professionals, and healthcare system): a systematic literature review

Use of the BRANT-MERQS scoring table for the quality assessment of type 3 medication review in patients with rheumatoid arthritis and those with type 2 diabetes mellitus

Potentially inappropriate prescribing among older adults with hypertension in China: prevalence and related comorbidities across different outpatient settings

Cost-effectiveness of pembrolizumab plus chemotherapy vs. chemotherapy as first-line treatment for advanced biliary tract cancer in China and the US

Assessing the real-world safety of tralokinumab for atopic dermatitis: insights from a comprehensive analysis of FAERS data

Self-medication of adults and children in Poland - results from outpatient health care physicians online questionnaire

A disproportionality analysis of low molecular weight heparin in the overall population and in pregnancy women using the FDA adverse event reporting system (FAERS) database

Adverse event reporting of the IGF-1R monoclonal antibody teprotumumab: a real-world study based on the US food and drug administration adverse event reporting system

Impact of changes in antihypertensive medication on treatment intensity at hospital discharge and 30 days afterwards

Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS)

History of trastuzumab: a case study in health technology reassessment and natural disinvestment in Veneto Region

Real-world pharmacovigilance analysis of galsulfase: a study based on the FDA adverse event reporting system (FAERS) database

Retrospective analysis of the effect of SGLT-2 inhibitors on renal function in patients with type 2 diabetes in the real world